J.P. Morgan analyst Anupam Rama initiated coverage with a Buy rating on Rallybio (RLYB – Research Report) on December 9 and set a price target of $21.00. The company’s shares closed last Friday at $4.93.
According to TipRanks, Rama is a 3-star analyst with an average return of 2.1% and a 44.14% success rate. Rama covers the Healthcare sector, focusing on stocks such as CytomX Therapeutics, Kodiak Sciences, and Elevation Oncology.
Currently, the analyst consensus on Rallybio is a Strong Buy with an average price target of $23.00, a 366.53% upside from current levels. In a report released on December 1, JMP Securities also reiterated a Buy rating on the stock with a $29.00 price target.
See today’s best-performing stocks on TipRanks >>
RLYB market cap is currently $182.6M and has a P/E ratio of -2.42.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Read More on RLYB:
